(1) I love the concept here, but a 3% equity stake in a biotech startup will undoubtedly take a long time to pay off. Bearing that in mind (and the fact that the company will need funds to keep the doors open), can you talk a little more about the revenue generating events and...

Hi Kevin, Thanks so much for the enthusiam. We actually didn’t mean to make the page public just yet as it is a work in progress, but these are really great questions. (1) Brazen Bio takes a long view and is building value through a portfolio approach through our various programs described elsewhere. We are not a fund. As such, our main near-term priority is the incubator and our Brazen Fellows. Until we build the additional revenue streams, we intend to capitalize through additional fundrais...

Is the 3% equity the only stake you will have in startups, or will you also be pursuing other options (e.g., warrants that will allow you to purchase additional equity if a startup is successful)?

Great question. We plan to launch a fund in parallel to invest pro-rata in our portfolio companies. At this time—per our goal of "founder friendly first"—we have no plans to include warrants or other similar features in our agreement. Instead, as we build traction, we will likely ask for more equity upfront. Thank you!

is there a place we can see the startups you are incubating at this point? Also, are there other incubators and how do you compare?

Hi Manoj! We are just launching ourselves and the intake process for Brazen Fellows is underway. Brazen Bio is unique because we are a fully independent, turnkey solution for biotech founders. Please read the Company FAQ (see button above) for more details. Thanks so much!

Will you be allowing animal testing to be used by the startups accepted by Brazen Bio?

Thanks, Jefferson. Our goal at Brazen Bio is to help scientific founders bring their innovations to patients by supporting them at the earliest stages. In many cases, this early proof of concept work can be carried out in vitro (e.g., test tubes, cell culture). At this time—for drugs/therapeutics—regulators do require in vivo preclinical pharmacology and safety data prior to human clinical trials and market approval. This may or may not be required for diagnostics.

Hello, do you have any direct competitors in this space, not just other incubators and if so, are your differentiators that you only take a 3% stake & that you offer access to lab space without all of the constraints that universities have? Hi Shawn, thank you for your qui...

Great question! There are many organizations/clubs that support biotech founders, usually loosely or formally affiliated with universities and local governments. We don’t really see them as competition, but potential partners because there is so much unmet medical need and plenty of rising bioentrepreneurs who need help. In fact, we have an active outreach effort underway. For example, I serve as an advisor for the LA branch of the national organization, Nucleate Bio (formerly known as Activa...

Brazen Bio

Helping biotech founders advance human health

$1,700

of a $250,000 goal

RESERVE

min $100

INVESTMENT TERMS

Convertible Note

Uncapped

6% interest

Pitch Video

Investor Panel

brazen.bio

Los Angeles, CA

Updates

Posts

Brazen Bio

Quick facts

Team profiles

$1,700

Updates